New drug combo shows promise in early tumor trial
NCT ID NCT04375267
First seen Apr 29, 2026 · Last updated May 17, 2026 · Updated 5 times
Summary
This early-stage study tested a combination of a radioactive drug (177Lu-DOTA-TATE) and a targeted pill (olaparib) in 18 adults with certain tumors that have a specific marker. The goal was to find the safest dose and understand side effects. This approach aims to make tumor cells more sensitive to radiation, potentially improving treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dept of Oncology
Gothenburg, 41345, Sweden
Conditions
Explore the condition pages connected to this study.